Strengthens Intellectual Property Estate for REQORSA Oncology Program with Immune Checkpoint Inhibitors AUSTIN, Texas, Aug. 18, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing...
Related Questions
What is the expected timeline for clinical milestones and potential revenue from the REQORSA oncology program with PD‑1/PD‑L1 antibodies?
How does Genprex's IP position compare to other gene‑therapy companies, and could it enable licensing or partnership opportunities?
How will the expanded patent portfolio for Reqorsa® affect Genprex's valuation and near‑term stock price?